Furthermore, the upregulation of AIM2 has been observed in various cancers, including lung cancer, RCC, OSCC, and CSCC, where it has been shown to enhance cell viability, invasiveness, and suppress apoptosis primarily via the JAK/STAT3 pathway, inhibition of iron death, and the NF-κB signaling pathway, ultimately promoting tumorigenesis. This evidence concerns the gene NFKB1 and lung carcinoma.